Clinical trials: Stage II Rectal Cancer
Unresectable Locally Recurrent Rectal Cancer
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
This is a prospective study to delve into the therapeutic benefits of combining stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer…
- Trial name
- NCT06767007
- Testing
- Stereotactic Body Radiation Therapy (SBRT), PD1, Chemotherapy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer, Colon Cancer
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab.
- Conditions
- Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
- Trial name
- NCT01206530
- Testing
- Hydroxychloroquine, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Neoplasm, Colorectal Cancer
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
The main clinical hypothesis is that compared to radio-chemotherapy for low and mid rectal tumors or surgery for high rectal tumors neoadjuvant chemotherapy reduces the rate of distant relapse without increasing the rate of local…
- Conditions
- Colorectal Neoplasm, Colorectal Cancer, Rectal Neoplasms, Chemotherapy Effect
- Trial name
- NEOLAR (NCT03280407)
- Testing
- Capecitabine, FOLFOX regimen (oxaliplatin/leucovorin/5FU), CAPOX (oxaliplatin/capecitabine)
- Where
- Denmark
- Volunteers
- 124 people
- Sponsor
- Zealand University Hospital
Anal Cancer Squamous Cell
Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)
Phase II randomized study of the use of pre-and probiotics during the definitive treatment of chemotherapy-radiotherapy (Ch-RT) for patients with localized anal canal squamous cell cancer (ACSCC) with the objective of increasing…
- Trial name
- BISQUIT (NCT03870607)
- Testing
- prebiotics in combination with probiotics
- Where
- Brazil
- Volunteers
- 75 people
- Sponsor
- AC Camargo Cancer Center
Rectal Cancer
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer
Irinotecan is one of effective drugs for colorectal cancer. In neoadjuvant chemoradiotherapy (CRT), Irinotecan is prescribed in a low dose of 50mg/m2/week because of toxicity.
- Trial name
- NCT01474187
- Testing
- Irinotecan, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Resected Colon Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells.
- Trial name
- NCT00378716
- Testing
- 5-fluorouracil, leucovorin calcium, tegafur
- Volunteers
- 1,608 people
- Sponsor
- NSABP Foundation Inc
Metastatic Colorectal Cancer
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional chemotherapy with the FOLFOX regimen as…
- Trial name
- NCT02128425
- Testing
- FOLFOXIRI, FOLFOX
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
*As of June 2026- Phase I has been completed and we are now in Phase II. This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photodynamic therapy for improving…
- Conditions
- Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
- Trial name
- NCT06307548
- Testing
- Aminolevulinic Acid, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Since its introduction, 5-fluorouracil (5-FU) has been the cornerstone of treatment for metastatic colorectal cancer (mCRC). Meanwhile the oral 5FU pro-drug Capecitabine (Xeloda®) proved equivalence to 5-FU and is a well…
- Trial name
- PASSION (NCT02119026)
- Testing
- Capecitabine, Bevacizumab, Oxaliplatin
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Prof. Dr. Werner Scheithauer
Colorectal Cancer
Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PETACC-6 (NCT00766155)
- Testing
- capecitabine, oxaliplatin
- Volunteers
- 1,094 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC)
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab.
- Conditions
- Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
- Trial name
- NCT06784947
- Testing
- Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Rectal Cancer Stage II, Rectal Cancer Stage III
Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma
The objective of the study is to provide proof that a MRI based preoperative radiochemotherapy in patients with locally advanced rectal carcinoma allows limiting RCT to high risk patients without increase of locoregional…
- Trial name
- OCUM (NCT01325649)
- Testing
- total mesorectal excision / long course radiochemotherapy, long course 5-FU bases radiochemotherapy
- Where
- Germany
- Volunteers
- 1,051 people
- Sponsor
- Johannes Gutenberg University Mainz
Anal Cancer
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00423293
- Testing
- fluorouracil, mitomycin C, Intensity-modulated radiation therapy
- Where
- 172 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Rectal Adenocarcinoma
Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
The purpose of the study is to evaluate the efficacy and safety of the combination of cytotoxic chemotherapy (Oxaliplatin and 5Fu) with bevacizumab concomitantly with radiotherapy as neoadjuvant treatment for patients with…
- Trial name
- New Beat (NCT01554059)
- Testing
- Bevacizumab, Oxaliplatin, 5-FU
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Metastasis
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
The purpose of this study is to compare progression free survival rates of metastasized colorectal cancer patients refractory or intolerant to systemic therapy with fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy and…
- Trial name
- SUNRISE-CRC (NCT03909724)
- Testing
- Sunitinib Malate, TAS 102
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Colorectal Cancer
Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or without ACE polymorphisms in terms of Progression-free survival (PFS).
- Trial name
- POLAF (NCT02970916)
- Testing
- FOLFIRI+aflibercept
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Stage II Rectal Cancer, Organ Preservation
Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam…
- Conditions
- Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III)
- Trial name
- MORPHEUS (NCT03051464)
- Testing
- Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost
- Where
- 4 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Rectal Cancer
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Patients diagnosed with locally advanced very low rectal cancer were chosen to participate in a comprehensive neoadjuvant therapy (TNT) protocol.
- Trial name
- TRACE-LE (NCT05969847)
- Testing
- split-course hypofraction radiotherapy, CAPOX, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- 池畔
Recurrent Rectal Cancer, Stage IIA Rectal Cancer
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
This phase I trial studies the side effects and best dose of trametinib when given together with fluorouracil and radiation therapy before surgery in treating patients with stage II-III rectal cancer.
- Conditions
- Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer
- Trial name
- NCT01740648
- Testing
- trametinib, fluorouracil, radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.